Starting a Phase 1 trial for RadioGel® Precision Radionuclide Therapy™ in patients with cancerous lymph nodes is a strategically smart decision for several reasons. Lymph nodes are critical sites in cancer progression, often acting as gateways for metastatic spread. By targeting cancerous nodes, the trial focuses on an area of high clinical relevance where effective localized treatment could have meaningful therapeutic and palliative impacts. Additionally, lymph nodes are relatively accessible for imaging and treatment delivery, simplifying the process of demonstrating precision placement and monitoring outcomes—key goals in a Phase 1 trial. This approach allows Vivos to highlight the safety and precision of RadioGel® in a real-world scenario while addressing an urgent medical need in advanced cancers.
Moreover, there is a compelling hypothesis that treating cancerous lymph nodes could indirectly benefit the primary tumor. Research suggests that lymph nodes play a crucial role in immune system interactions and tumor microenvironment dynamics. By effectively treating metastatic nodes, the therapy might reduce the spread of cancer cells and potentially weaken the tumor’s systemic support. This opens the door for synergistic effects when used alongside other treatments, such as chemotherapy or immunotherapy. Demonstrating such outcomes in this trial could position RadioGel® as a highly versatile tool in oncology, paving the way for broader applications in treating both primary and secondary cancers.
Market Data 
Markets 
AI
